Monoclonal antibodies (mAbs) have great potential to counter biological warfare agents that are not addressed by currently available countermeasures. mAbs display exquisite specificity, are able to recruit host immune components to fight infection, confer near-immediate immunity once administered, can be successfully administered to all populations regardless of current immune status, and have a generally low rate of adverse reactions. The Industrialization Core's main responsibility will be to lead the translational research effort for the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VHF-IC). The members of the Core have extensive experience with translating mAb research concepts into IND-enabling preclinical therapeutics for infectious diseases. The Core will make use of a rapid antibody manufacturing platform (RAMP) to provide well characterized, highly purified homogenous mAb preparations to facilitate direct comparisons between different mAbs by the individual Research Projects and Cores C and D. The Industrialization Core will be responsible for management of the advancement of products generated by the Research Projects through IND-enabling studies.
In Specific Aim 1, to quickly and economically address the supply needs for the Research Projects and Structure and Virology Cores, the Industrialization Core will produce all ofthe VHF-IC mAbs using the RAMP Nicotiana benthamlana manufacturing system. The Industrialization Core will ensure that all Research Projects and Cores C and D are using well-characterized mAbs with homogenous mammalian N-glycoforms that are produced and purified using a single protocol.
In Specific Aim 2, the Industrialization Core will be responsible for advancing the lead products selected from the three Research Projects by the Product Development Team through preclinical development.The Product Development Team will be responsible for prioritizing products and allocating Core resources appropriately and will work closely with the sponsoring companies (Mapp/Defyrus for filovirus products;Zaigen for arenavirus products) who will ultimately be responsible for developing the products after completion ofthe VHF-IC effort.
The filoviruses and arenaviruses are highly pathogenic viruses that cause rapidly progressing hemorrhagic fever. There are currently no FDA approved therapies or vaccines to treat infections with these viruses. The goal of this work is to develop therapeutic monoclonal antibodies that are effective against these deadly pathogens.
|Liu, Guodong; Wong, Gary; Su, Shuo et al. (2017) Clinical Evaluation of Ebola Virus Disease Therapeutics. Trends Mol Med 23:820-830|
|Wong, Gary; Mendoza, Emelissa J; Plummer, Francis A et al. (2017) From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opin Biol Ther :1-15|
|Hofmann, Daniel; Lai, Jonathan R (2017) Exploring Human Antimicrobial Antibody Responses on a Single B Cell Level. Clin Vaccine Immunol 24:|
|Nyakatura, Elisabeth K; Soare, Alexandra Y; Lai, Jonathan R (2017) Bispecific antibodies for viral immunotherapy. Hum Vaccin Immunother 13:836-842|
|Zhao, Xuelian; Howell, Katie A; He, Shihua et al. (2017) Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell 169:891-904.e15|
|Mire, Chad E; Geisbert, Joan B; Borisevich, Viktoriya et al. (2017) Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 9:|
|He, Jing; Melnik, Lilia I; Komin, Alexander et al. (2017) Ebola Virus Delta Peptide is a Viroporin. J Virol :|
|Fausther-Bovendo, H; Qiu, X; McCorrister, S et al. (2017) Ebola virus infection induces autoimmunity against dsDNA and HSP60. Sci Rep 7:42147|
|Wec, Anna Z; Herbert, Andrew S; Murin, Charles D et al. (2017) Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell 169:878-890.e15|
|Kroeker, Andrea; He, Shihua; de La Vega, Marc-Antoine et al. (2017) Characterization of Sudan Ebolavirus infection in ferrets. Oncotarget 8:46262-46272|
Showing the most recent 10 out of 42 publications